Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical ...

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been ...

Frier Levitt will host a May 15 webinar on legal risks, compounding regulations and market trends impacting GLP-1 prescribers ...

Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

A new analysis being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), finds that around half of the 100 top ...

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.

Shares of American Eagle Outfitters are tumbling before Wednesday's opening bell after the retailer withdrew its financial ...

Liver fibrosis is a gradually worsening condition marked by excessive collagen buildup resulting from ongoing liver damage.